Immune Therapy in Myelodysplastic Syndromes

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Antithymocyte globulin (ATG) - Administering a drug that suppresses the immune system—a technique called immunosuppression—appears to provide some benefit in the treatment of myelodysplastic syndromes (MDS). ATG is the best immunosuppressive agent for the treatment of patients with severe aplastic anemia (a type of bone marrow disease) and produces results rivaling those of stem cell transplantation. This drug has also demonstrated activity in the treatment of patients with MDS. 

Clinical trial results suggest that more than 43 percent of patients with MDS respond to immunosuppression with ATG. This response lasted nearly 2½ years (29 months) on average. Combinations of ATG, cyclosporine, and steroids produce response rates of 40 percent to 50 percent in lower risk MDS, which are durable for 2 to 3 years. 

This content was last modified on August 11, 2007 .
Latest Cancer News
“Scent” May Aid in Skin Cancer Diagnosis

August 21, 2008 — The concentration of certain molecules called volatile organic compounds (VOCs) given off by a cancer may ultimately contribute to accurate diagnosis of skin cancer. These results were recently presented at the 2008 annual American Chemical Society meeting.

Livial® Reduces Breast Cancer Risk but Increases Stroke Risk

August 21, 2008 — Livial® (tibolone), an agent used to reduce menopausal symptoms as well as bone loss, significantly reduces the risk of breast cancer and prevents bone loss and fractures in older postmenopausal women; however, it doubles the risk of stroke among postmenopausal women. These results were recently published in the New England Journal of Medicine.

Watchful Waiting Versus Radical Prostatectomy: 11-year Follow-up

August 21, 2008 — Researchers affiliated with the Scandinavian Prostatic Cancer Group Study Number 4 have reported the following: “Radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.” The details of the 3rd report of this randomized trial appeared in an early online publication in the Journal of the National Cancer Institute on August 11, 2008.

Select news items provided by Reuters Health